High prevalence of Wilms tumor 1 expression in multiple myeloma and plasmacytoma: A cohort of 142 Asian patients’ samples
Issued Date
2023-01-24
Resource Type
ISSN
12194956
eISSN
15322807
Scopus ID
2-s2.0-85147415141
Pubmed ID
36760714
Journal Title
Pathology and Oncology Research
Volume
29
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pathology and Oncology Research Vol.29 (2023)
Suggested Citation
Phikulsod P., Sukpanichnant S., Kunacheewa C., Chieochansin T., Junking M., Yenchitsomanus P.T. High prevalence of Wilms tumor 1 expression in multiple myeloma and plasmacytoma: A cohort of 142 Asian patients’ samples. Pathology and Oncology Research Vol.29 (2023). doi:10.3389/pore.2023.1610844 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82456
Title
High prevalence of Wilms tumor 1 expression in multiple myeloma and plasmacytoma: A cohort of 142 Asian patients’ samples
Author's Affiliation
Other Contributor(s)
Abstract
Wilms tumor 1 (WT1) is a promising target antigen for cancer immunotherapy. However, WT1 protein expression and its clinical correlation in multiple myeloma (MM) patients are still limited. We, therefore, investigated WT1 expression in 142 bone marrow and plasmacytoma samples of MM patients at different stages of the disease by immunohistochemistry. The correlations between WT1 expression and clinical parameters or treatment outcomes were evaluated. The overall positive rate of WT1 expression was 91.5%; this high prevalence was found in both bone marrow and plasmacytoma samples, regardless of the disease status. Cytoplasmic WT1 expression was correlated with high serum free light chain ratio at presentation. However, no significant association between WT1 expression and treatment outcome was observed. This study confirms the high prevalence of WT1 expression in an Asian cohort of MM, encouraging the development of immunotherapy targeting WT1 in MM patients, particularly in those with extramedullary plasmacytoma or relapsed disease.